|
|
|
|
| The biopharma space is full of big process intensification promises; increased capacity from smaller footprints, reduced raw material costs, improved sustainability, and measurable labor savings among them. What’s achievable, what batch processes are real-world biopharmaceutical manufacturers intensifying today, and what’s next on the path to continuous manufacturing? Find out by joining the discussion on June 11th. Registration for this live and interactive discussion is free! |
|
|
|
|
By Business Of Biotech Podcast | Back by popular demand, biopharma industry opinionator extraordinaire Allan Shaw rejoins the Business of Biotech to expose the murky role Pharmacy Benefit Managers (PBMs) play in the last, costly mile of the drug distribution supply chain. Allan pulls no punches in his criticism of the current rebate structure and shares why the model leaves patients and manufacturers stuck with the spiraling tab. |
|
|
| Resolving Common Single-Use Concerns | Article | By Evan Hagen, Charter Medical | Demand for single-use production tools, components, expertise, and capabilities continues to grow as innovative cell therapies evolve, however concerns regarding these solutions are on the rise as well. |
|
|
|
| New Container Protects Bulk Frozen Biopharmaceuticals | Q&A | W.L. Gore & Associates | Learn more about a flexible freeze container that maintains package integrity after freezing at -86 °C. (-123 °F) through its durable design, minimizing product loss due to package failure. |
|
|
|
|
|
|
|
|
By Ana-Zeralda Canals Hamann, Debiopharm | The magnitude of serialization, especially for firms with extensive portfolios and intricate supply chains, poses serious challenges. This discussion offers solutions. |
|
|
|
| Transitioning From Vial To Prefilled Syringe | Article | By Natasha Van Rutten, Catalent | Understand how formulation development for a prefilled syringe affects manufacturing, driving the industry toward optimizing delivery of injectable products and, ultimately, improving patient care. |
|
|
| A Risk-Based Approach To Injectable Combination Product Development | White Paper | By Fran DeGrazio, Diane Paskiet, and Peggy Frandolig, West Pharmaceutical Services, Inc. | Examine how to establish a holistic approach to drug-device combination product (DDCP) development and how to assess and manage risk throughout the development and approval process. |
|
|
|
|
|
|
| Connect With Bioprocess Online: |
|
|
|
.png)
